More than a decade after initial concerns about the safety of COX-2 inhibitors, the PRECISION trial has shown celecoxib is non-inferior to either ibuprofen or naproxen in respect to cardiovascular risk. The study published in the New England Journal of Medicine found 200mg/day of celecoxib for arthritic pain did not increase the risk of major ...
Celecoxib verdict in but study ‘imperfect’
By Mardi Chapman
17 Nov 2016